What the FDA labels say about taking them together
Dolutegravir and oxcarbazepine
Dolutegravir's FDA label of May 22, 2026 names oxcarbazepine in its drug interactions section; the oxcarbazepine labels PlainMeds reads (2) do not name dolutegravir. The dolutegravir label: “Avoid coadministration with TIVICAY or TIVICAY PD because there are insufficient data to make dosing recommendations.”
Check it at the source: the dolutegravir FDA label on DailyMed (effective May 22, 2026, ST. MARY'S MEDICAL PARK PHARMACY); the oxcarbazepine FDA label on DailyMed (effective December 16, 2025, Novartis Pharmaceuticals Corporation).
What does the dolutegravir label say about oxcarbazepine?
Dolutegravir label, drug interactionsConcomitant Drug Class/Drug Name: Oxcarbazepine Phenytoin Phenobarbital St. John’s wort ( Hypericum perforatum); Effect on Concentration of Dolutegravir and/or Concomitant Drug: ↓Dolutegravir; Clinical Comment: Avoid coadministration with TIVICAY or TIVICAY PD because there are insufficient data to make dosing recommendations.
Source: FDA drug label (Tivicay), NDA204790 (Viiv Hlthcare), as published by ST. MARY'S MEDICAL PARK PHARMACY, effective May 22, 2026 (SPL set 485bc9db-8665-9f5a-e063-6394a90a7921), via openFDA; the full label on DailyMed
What does the oxcarbazepine label say about dolutegravir?
Oxcarbazepine's label (effective December 16, 2025) and its 1 other brand-application label do not name dolutegravir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Trileptal), Novartis Pharmaceuticals Corporation, effective December 16, 2025 (SPL set 4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dolutegravir | Oxcarbazepine | |
|---|---|---|
| Labeled for | HIV | Seizures and epilepsy |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $77.64 per tablet 50 mg tablet | $0.167 per tablet 300 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once